Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses

被引：3

作者：

Awad, Ahmed M. ^{[1
]}

Hansen, Kamryn ^{[1
]}

Del Rio, Diana ^{[1
]}

Flores, Derek ^{[1
]}

Barghash, Reham F. ^{[2
]}

Kakkola, Laura ^{[3
]}

Julkunen, Ilkka ^{[3
,4
]}

Awad, Kareem ^{[3
,5
]}

机构：

[1] Calif State Univ Channel Isl, Dept Chem, Camarillo, CA 93012 USA

[2] Inst Chem Ind Res, Natl Res Ctr, Cairo 12622, Egypt

[3] Univ Turku, Inst Biomed, Fac Med, Turku 20014, Finland

[4] Turku Univ Hosp, Clin Microbiol, Turku 20521, Finland

[5] Natl Res Ctr, Inst Pharmaceut & Drug Ind Res, Dept Therapeut Chem, Cairo 12622, Egypt

来源：

BIOMOLECULES | 2023年 / 13卷 / 10期

关键词：

coronavirus; COVID-19; target cell responses; drug design; nucleoside analogs; ACE2; RESPIRATORY SYNDROME CORONAVIRUS; VIRAL DISEASES; EBOLA-VIRUS; MERS-COV; SARS-COV-2; SARS; INFECTION; PATHOGENESIS; RIBAVIRIN; EFFICACY;

D O I：

10.3390/biom13101452

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In light of the COVID-19 global pandemic caused by SARS-CoV-2, ongoing research has centered on minimizing viral spread either by stopping viral entry or inhibiting viral replication. Repurposing antiviral drugs, typically nucleoside analogs, has proven successful at inhibiting virus replication. This review summarizes current information regarding coronavirus classification and characterization and presents the broad clinical consequences of SARS-CoV-2 activation of the angiotensin-converting enzyme 2 (ACE2) receptor expressed in different human cell types. It provides publicly available knowledge on the chemical nature of proposed therapeutics and their target biomolecules to assist in the identification of potentially new drugs for the treatment of SARS-CoV-2 infection.

引用

页数：28

共 228 条

[111] Current evidence on the use of anakinra in COVID-19 [J].

Khani, Elnaz ;

Shahrabi, Marzieh ;

Rezaei, Haleh ;

Pourkarim, Fariba ;

Afsharirad, Hoda ;

Solduzian, Mohammad .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 111

[112] Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CLpro) [J].

Koulgi, Shruti ;

Jani, Vinod ;

Uppuladinne, Mallikarjunachari ;

Sonavane, Uddhavesh ;

Nath, Asheet Kumar ;

Darbari, Hemant ;

Joshi, Rajendra .

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (15) :5735-5755

[113] Intermediate- to high-dose dexamethasone versus low-dose dexamethasone in patients with COVID-19 requiring respiratory support: a systematic review and meta-analysis of randomized trials [J].

Kow, Chia Siang ;

Ramachandram, Dinesh Sangarran ;

Hasan, Syed Shahzad .

INFLAMMOPHARMACOLOGY, 2023, 31 (05) :2773-2779

[114] Disease-drug and drug-drug interaction in COVID-19: Risk and assessment [J].

Kumar, Devendra ;

Trivedi, Neerja .

BIOMEDICINE & PHARMACOTHERAPY, 2021, 139

[115] Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis [J].

Kyriakopoulos, Christos ;

Ntritsos, Georgios ;

Gogali, Athena ;

Milionis, Haralampos ;

Evangelou, Evangelos ;

Kostikas, Konstantinos .

RESPIROLOGY, 2021, 26 (11) :1027-1040

[116] SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant [J].

Laine, Larissa ;

Skon, Marika ;

Vaisanen, Elina ;

Julkunen, Ilkka ;

Osterlund, Pamela .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[117] Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus [J].

Leneva, Irina ;

Kartashova, Nadezhda ;

Poromov, Artem ;

Gracheva, Anastasiia ;

Korchevaya, Ekaterina ;

Glubokova, Ekaterina ;

Borisova, Olga ;

Shtro, Anna ;

Loginova, Svetlana ;

Shchukina, Veronika ;

Khamitov, Ravil ;

Faizuloev, Evgeny .

VIRUSES-BASEL, 2021, 13 (08)

[118] The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19 [J].

Li, Kun ;

Meyerholz, K. David ;

Bartlett, A. Jennifer ;

McCray, B. Paul, Jr. .

MBIO, 2021, 12 (04)

[119] Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial [J].

Li, Yueping ;

Xie, Zhiwei ;

Lin, Weiyin ;

Cai, Weiping ;

Wen, Chunyan ;

Guan, Yujuan ;

Mo, Xiaoneng ;

Wang, Jian ;

Wang, Yaping ;

Peng, Ping ;

Chen, Xudan ;

Hong, Wenxin ;

Xiao, Guangming ;

Liu, Jinxin ;

Zhang, Lieguang ;

Hu, Fengyu ;

Li, Feng ;

Zhang, Fuchun ;

Deng, Xilong ;

Li, Linghua .

MED, 2020, 1 (01) :105-+

[120] Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus [J].

Liang, Weicheng ;

Feng, Zhijie ;

Rao, Shitao ;

Xiao, Cuicui ;

Xue, Xingyang ;

Lin, Zexiao ;

Zhang, Qi ;

Qi, Wei .

GUT, 2020, 69 (06) :1141-+

← 7 8 9 10 11 12 13 14 15 16 →